CUE - Cue Biopharma
Cue Biopharma Logo

CUE - Cue Biopharma

https://www.cuebiopharma.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
Bullish
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
GlobeNewswire • 2 months, 3 weeks ago • score: 0.35
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming ...
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.

52W High
$1.99
52W Low
$0.45
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.59
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.76
EV/Revenue (<3 favorable)
4.84
P/S (TTM) (<3 favorable)
7.23
P/B (<3 favorable)
3.30
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
0.35%
Institutions (25–75% balanced)
22.62%
Shares Outstanding
76,846,000
Float
76,580,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
8,286,000
Gross Profit (TTM)
-24,737,000
EPS (TTM)
-0.51
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-2.92%
ROE (TTM) (>15% strong)
-1.96%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.11
Momentum
Bearish momentum
Value
-0.0153
Previous
-0.0119
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025